Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

107.09USD
17 Jul 2019
Change (% chg)

$-1.73 (-1.59%)
Prev Close
$108.82
Open
$109.35
Day's High
$109.61
Day's Low
$107.08
Volume
1,340,570
Avg. Vol
2,252,710
52-wk High
$132.12
52-wk Low
$88.18

Latest Key Developments (Source: Significant Developments)

Gilead Appoints Christi L. Shaw As CEO Of Kite
Friday, 12 Jul 2019 

July 11 (Reuters) - Gilead Sciences Inc ::GILEAD APPOINTS CHRISTI L. SHAW AS CHIEF EXECUTIVE OFFICER OF KITE.GILEAD SCIENCES INC - SHAW CURRENTLY SERVES AS SENIOR VICE PRESIDENT OF ELI LILLY &. CO., AND PRESIDENT OF LILLY BIO-MEDICINES.  Full Article

Lilly Announces Changes In Senior Leadership
Thursday, 11 Jul 2019 

July 11 (Reuters) - Eli Lilly and Co ::LILLY ANNOUNCES CHANGES IN SENIOR LEADERSHIP.ELI LILLY AND CO - CHRISTI SHAW TO LEAVE LILLY; PATRIK JONSSON WILL BE PROMOTED TO LEAD LILLY BIO-MEDICINES.ELI LILLY AND CO - PATRIK JONSSON WILL BE PROMOTED TO LEAD LILLY BIO-MEDICINES.ELI LILLY AND CO - MIKE HARRINGTON, SENIOR VICE PRESIDENT AND GENERAL COUNSEL, TO RETIRE AT YEAR END.ELI LILLY AND CO - PATRIK JONSSON, CURRENTLY PRESIDENT AND GENERAL MANAGER OF LILLY JAPAN, WILL SUCCEED SHAW.ELI LILLY AND CO - A SEARCH IS UNDERWAY FOR HARRINGTON'S SUCCESSOR..ELI LILLY - JONSSON WILL BE PROMOTED TO SENIOR VICE PRESIDENT & PRESIDENT OF LILLY BIO-MEDICINES PENDING COMPLETION OF WORK AUTHORIZATION IN U.S..ELI LILLY AND CO - CHRISTI SHAW, SENIOR VICE PRESIDENT AND PRESIDENT LILLY BIO-MEDICINES, HAS ANNOUNCED SHE WILL LEAVE LILLY AT END OF AUGUST.  Full Article

Ibri In License Agreement For Access To Lilly’S Fab Phage Display Library
Friday, 21 Jun 2019 

June 20 (Reuters) - Eli Lilly and Co ::IBRI IN LICENSE AGREEMENT FOR ACCESS TO LILLY’S FAB PHAGE DISPLAY LIBRARY.INDIANA BIOSCIENCES RESEARCH INSTITUTE - ENTERED INTO LICENSE AGREEMENT WITH ELI LILLY FOR IBRI TO ACCESS LILLY'S PROPRIETARY FAB PHAGE DISPLAY LIBRARY.  Full Article

Amgen Sues HHS On Rule Requiring Drug Prices In TV Ads
Saturday, 15 Jun 2019 

June 14 (Reuters) - Amgen Inc ::AMGEN INC - ON JUNE 14, AMGEN, MERCK, LILLY, AND ASSOCIATION OF NATIONAL ADVERTISERS, FILED SUIT IN U.S. DISTRICT COURT FOR THE DISTRICT OF COLUMBIA.AMGEN - LAWSUIT SEEKS TO PREVENT U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES' MAY 10 RULE REQUIRING TV ADVERTISEMENTS TO STATE LIST PRICE OF DRUGS.  Full Article

Trulicity Significantly Reduced Major Cardiovascular Events For Broad Range Of People With Type 2 Diabetes
Monday, 10 Jun 2019 

June 9 (Reuters) - Eli Lilly and Co ::TRULICITY® (DULAGLUTIDE) SIGNIFICANTLY REDUCED MAJOR CARDIOVASCULAR EVENTS FOR BROAD RANGE OF PEOPLE WITH TYPE 2 DIABETES.REWIND DATA SHOWED A CONSISTENT EFFECT IN PEOPLE WITH AND WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE.REWIND RESULTS HAVE BEEN SUBMITTED TO REGULATORY AUTHORITIES IN U.S. AND EUROPE FOR REVIEW.  Full Article

Lilly's Ultra Rapid Lispro Provided Similar A1c Reductions Compared To Humalog, With Superior Post-Meal Blood Glucose Reductions
Sunday, 9 Jun 2019 

June 9 (Reuters) - Eli Lilly and Co ::LILLY'S ULTRA RAPID LISPRO PROVIDED SIMILAR A1C REDUCTIONS COMPARED TO HUMALOG (INSULIN LISPRO), WITH SUPERIOR POST-MEAL BLOOD GLUCOSE REDUCTIONS.ELI LILLY- TWO PHASE 3 STUDIES, PRONTO-T1D & PRONTO-T2D, EVALUATED SAFETY & EFFICACY OF URLI VERSUS HUMALOG IN ADULTS WITH TYPE 1 & TYPE 2 DIABETES, RESPECTIVELY.ELI LILLY- BOTH STUDIES MET PRIMARY ENDPOINT OF NON-INFERIOR A1C REDUCTION FROM BASELINE COMPARED TO HUMALOG AT 26 WEEKS, WHEN INSULINS WERE DOSED AT MEALTIME.ELI LILLY- LILLY SUBMITTED APPLICATIONS FOR URLI WITH REGULATORY AUTHORITIES IN EUROPE AND JAPAN AND PLANS TO SUBMIT IN U.S. LATER THIS YEAR.  Full Article

FDA Approves Lilly's Emgality As First Ever Cluster Headache Treatment
Wednesday, 5 Jun 2019 

June 4 (Reuters) - Eli Lilly and Co ::FDA APPROVES FIRST TREATMENT FOR EPISODIC CLUSTER HEADACHE THAT REDUCES THE FREQUENCY OF ATTACKS.FDA - APPROVED EMGALITY (GALCANEZUMAB-GNLM) SOLUTION FOR INJECTION FOR TREATMENT OF EPISODIC CLUSTER HEADACHE IN ADULTS.FDA - GRANTED APPROVAL OF EMGALITY TO ELI LILLY.  Full Article

Eli Lilly and Co says co's Cyramza Becomes First FDA-Approved Biomarker-Driven Therapy In Patients With Hepatocellular Carcinoma
Monday, 13 May 2019 

May 13 (Reuters) - Eli Lilly and Co ::LILLY'S CYRAMZA® (RAMUCIRUMAB) BECOMES FIRST FDA-APPROVED BIOMARKER-DRIVEN THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.ELI LILLY AND CO - CONCURRENT WITH THIS APPROVAL, FDA HAS ALSO REMOVED BOXED WARNING FROM CYRAMZA LABELING.ELI LILLY AND CO - APPROVAL IS BASED ON RESULTS FROM REACH-2 STUDY, FIRST POSITIVE PHASE 3 HCC TRIAL IN A BIOMARKER-SELECTED PATIENT POPULATION.  Full Article

Lilly Announces Sale Of Legacy Antibiotics Brands And Manufacturing Facility In China
Tuesday, 23 Apr 2019 

April 22 (Reuters) - Eli Lilly and Co ::LILLY ANNOUNCES SALE OF LEGACY ANTIBIOTICS BRANDS AND MANUFACTURING FACILITY IN CHINA.WILL RECEIVE A DEPOSIT OF $75 MILLION, FOLLOWED BY A PAYMENT OF $300 MILLION UPON SUCCESSFUL CLOSING OF TRANSACTION.ENTERED IAGREEMENT TO SELL RIGHTS IN CHINA FOR TWO LEGACY LILLY ANTIBIOTIC MEDICINES, CECLOR AND VANCOCIN.ENTERED AGREEMENT TO SELL RIGHTS IN CHINA A MANUFACTURING FACILITY IN SUZHOU, CHINA THAT PRODUCES CECLOR, TO EDDINGPHARM.WILL PROVIDE ONGOING SERVICES TO EDDINGPHARM FOR PERIOD OF TIME TO ENSURE CONTINUITY OF PRODUCT SUPPLY, SUPPORT SMOOTH TRANSITION.TRANSACTION IS EXPECTED TO CLOSE IN EITHER LATTER PART OF 2019 OR EARLY 2020.TRANSACTION WILL NOT BE REFLECTED IN LILLY'S REPORTED RESULTS AND FINANCIAL GUIDANCE UNTIL CLOSING.  Full Article

Lilly's Taltz Meets Main Goal In Study Of Patients With Non-Radiographic Axial Spondyloarthritis
Monday, 22 Apr 2019 

April 22 (Reuters) - Eli Lilly and Co ::LILLY ANNOUNCES POSITIVE TOP-LINE RESULTS FOR COAST-X, A 52-WEEK PLACEBO-CONTROLLED STUDY OF TALTZ® (IXEKIZUMAB) IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS.ELI LILLY AND CO - TALTZ MET PRIMARY AND ALL MAJOR SECONDARY ENDPOINTS IN COAST-X, A PHASE 3 STUDY.ELI LILLY AND CO - PLANS TO SUBMIT TO REGULATORY AUTHORITIES IN 2019 FOR APPROVAL FOR NR-AXSPA..ELI LILLY AND CO - IN COAST-X, SAFETY PROFILE OF TALTZ WAS CONSISTENT WITH PREVIOUSLY REPORTED PHASE 3 STUDIES OF TALTZ.ELI LILLY AND CO - IN COAST-X, NO NEW SAFETY SIGNALS WERE DETECTED.ELI LILLY AND CO - LILLY PLANS TO SUBMIT TO REGULATORY AUTHORITIES IN 2019 FOR APPROVAL FOR NR-AXSPA.  Full Article

UPDATE 1-Eli Lilly's bio-medicines head to leave next month

July 11 Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month.